Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK

[1]  C. Caldas,et al.  Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. , 2020, Health technology assessment.

[2]  C. Tournigand,et al.  6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial , 2019, The Lancet.

[3]  C. Caldas,et al.  6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial , 2019, The Lancet.

[4]  Lauren L. Ritterhouse,et al.  Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  David A. Chambers,et al.  Conceptualizing De-Implementation in Cancer Care Delivery. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Earl,et al.  PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  C. Caldas,et al.  PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. , 2018 .

[8]  V. Georgoulias,et al.  Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  I. Graham,et al.  “Entrenched practices and other biases”: unpacking the historical, economic, professional, and social resistance to de-implementation , 2015, Implementation Science.

[10]  Jorma Isola,et al.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.

[11]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[12]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.